EGF anticorps

N° du produit ABIN115994

Détail du produit anti-EGF anticorps

Antigène: EGF (Epidermal Growth Factor (EGF))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EGF est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA), Immunohistochemistry (Frozen Sections) (IHC (fro)), Functional Studies (Func)

Specificité: Human Epidermal Growth Factor (hEGF)

Purification: Affinity Chromatography using an immobilized Human EGF matrix

Immunogène: Highly pure (>98%) E.coli derived recombinant Human EGF (hEGF).

Information d'application

Indications d'application: ELISA: To detect hEGF by direct ELISA (using 100 l/well antibody solution) a concentrationof at least 0.5 μg/mL of this antibody is required. This antigen affinity purified antibody, inconjunction with compatible secondary reagents, allows the detection of 0.2-0.4 ng/wellof recombinant hEGF. Western Blot: To detect hEGF by Western Blot analysis this antibody can be used at aconcentration of 0.1-0.2 μg/mL. Used in conjunction with compatible secondary reagentsthe detection limit for recombinant hEGF is 1.5-3.0 ng/lane, under either reducing ornon-reducing conditions. Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity ofhEGF (2.0 ng/mL), a concentration of 0.25-0.35 μg/mL of this antibody is required. Immunohistochemistry: A starting dilution of 1 μg/mL is recommended for frozen sections. For paraffin embedded sections use microwave pretreatment, EDTA, pH 9 and a dilution of1-5 μg/mL.

Restrictions: For Research Use only

Stockage

Reconstitution: Restore in sterile water to a concentration of 0.1-1.0 mg/mL.

Concentration: 1.0 mg/mL

Buffer: PBS, pH 7.2 without preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Centrifuge vial prior to opening!

Stock: 4 °C

Détails sur EGF

Antigène: EGF (Epidermal Growth Factor (EGF))

Autre désignation: EGF (EGF Produits)

Synonymes: anticorps HOMG4, anticorps URG, anticorps AI790464, anticorps CEGF, anticorps epidermal growth factor, anticorps pro-epidermal growth factor, anticorps EGF, anticorps egf, anticorps CpipJ_CPIJ020278, anticorps Egf

Sujet: Epidermal growth factor (EGF) has a profound effect on the differentiation of specific cells in vivo and is a potent mitogenic factor for a variety of cultured cells. The EGF precursor is believed to exist as a membrane bound molecule which is proteolytically cleaved to generate the 53 amino acid peptide hormone that stimulates cells to divide. EGF exerts its actions by binding to the EGFR, a 170 kDa protein. Epidermal growth factor (EGF) is a key growth factor regulating cell survival. Through its binding to cell surface receptors, EGF activates an extensive network of signal transduction pathways that include activation of the PI3K/AKT, RAS/ERK and JAK/STAT pathways. Because of its key role in driving the proliferation of cells, EGFR is a target of several anti-cancer drugs currently in development.Synonyms: Epidermal growth factor, HOMG4, Pro-epidermal growth factor, URG, Urogastrone

ID gène: 1950

NCBI Accession: NP_001954

UniProt: P01133

Pathways: Signalisation NF-kappaB, Signalisation RTK, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Regulation of Carbohydrate Metabolic Process, Hepatitis C, Protein targeting to Nucleus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation